Node Negative Early Stage Breast Cancer Patients Benefit From Taxotere R -Based Chemotherapy

Sanofi-aventis and GEICAM (Grupo Espanol de Investigacion en Cancer de Mama) announced that for women with high-risk node-negative early stage breast cancer adjuvant treatment (post surgery) with Taxotere(R) (docetaxel) Injection Concentrate as part of the TAC regimen (Taxotere(R), dox.

First Patient Enrolled In Global Phase III Study Of Bevacizumab And Trastuzumab In Early Breast Cancer

A new international study for women with HER2-positive breast cancer is open for enrollment.

Addition Of Paclitaxel To Standard Chemotherapy Improves Outcome In Early Breast Cancer - May 27 JNCI

Early breast cancer patients treated with standard chemotherapy followed by paclitaxel had better disease-free survival compared with patients treated with standard therapy alone, according to the final results from a randomized phase III trial.Paclitaxel and other taxanes are among the most active agents in metastatic breast cancer.

University Of Pennsylvania Researcher To Launch Drug Trial In Chinese Province Among IDUs

David Metzger, director of the HIV/AIDS Prevention Research Division at the University of Pennsylvania, and colleagues plan to launch a trial in China among injection drug users to determine if a drug that reduces the craving for heroin also can reduce the spread of HIV through the sharing of contaminated needles, the.

AtheroGenics' ARISE Trial Results Published In The Lancet

AtheroGenics, Inc. (NASDAQ: AGIX), a pharmaceutical company focused on the treatment of chronic inflammatory diseases, announced that The Lancet, a peer-reviewed medical journal, will publish an article entitled, "Effects of succinobucol (AGI-1067) after an acute coronary syndrome: a randomized, double-blind, placebo-controlled trial, " in this week's May 24, 2008 issue.

Bavarian Nordic Has Initiated Phase I II Clinical Study With Its HIV Vaccine Candidate: MVA-BN R HIV Multiantigen

A Phase I/II safety and immunogenicity study in 15 HIV-infected patients(CD4 counts > 350 ul/ml) has begun enrolment in the United States. The firstsafety data are expected by the end of 2008, while the immunogenicity datawill be available during the first half of 2009.

When Your Memories Can No Longer Be Trusted

You went to a wedding yesterday. The service was beautiful, the food and drink flowed and there was dancing all night. But people tell you that you are in hospital, that you have been in hospital for weeks, and that you didn't go to a wedding yesterday at all.

Society Of Urologic Oncology Meeting - Bladder Cancer - Panel With Case Discussion

UroToday.com - Dr. Grossman started by discussing bladder markers. Biomarkers are now being incorporated into large phase III trials so that they can be robustly assessed. Biomarkers with a predictable cutoff, performed in a reliable laboratory hold promise.

Applications, Limitations, And Examples Of What One Can Do With In Vivo Optical Imaging In Translational Urologic Research

UroToday.com - Dr. Hickson from Abbott Laboratories discussed optical imaging and applications in urologic research. There are 2 methodologies: bioluminescence, which is an enzymatic process that has a high signal to noise ratio and fluorescence which is the absorption of a photon that triggers a reaction.

Patients With Acute Kidney Injury Do Not Have Improved Outcomes With More Intensive Dialysis

No significant difference in death rates or other outcomes was found between a group of patients with acute kidney injury that received intensive dialysis and another group that received a more standard regimen of dialysis, according to a joint Department of Veterans Affairs (VA) and National Institutes of Health (NIH) study published in the June issue of the New England Journal of Medicine.